Brief: Tiziana Life Sciences Announces Results From Second Patient With Secondary Progressive Multiple Sclerosis Following Three Months Of Dosing With Intranasal Foralumab
08/06/2022 13:36
June 8 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES ANNOUNCES POSITIVE CLINICAL RESULTS
IN THE
SECOND PATIENT WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
(SPMS) FOLLOWING THREE MONTHS OF DOSING WITH INTRANASAL
FORALUMAB
* TIZIANA LIFE SCIENCES - TREATMENT WITH FORALUMAB WAS
WELL-TOLERATED AND IMPROVED CLINICAL AND PET IMAGING ANALYSES
* TIZIANA LIFE SCIENCES - 2ND PATIENT SHOWED CLINICAL
IMPROVEMENTS
IN PET IMAGING ANALYSIS, NEUROLOGIC EXAM, TIMED 25-FOOT WALK
TEST, AFTER 3 MONTHS OF TREATMENT
* TIZIANA LIFE SCIENCES LTD - U.S. FDA HAS NOW ALLOWED
TIZIANA TO
TREAT AN ADDITIONAL EIGHT SPMS PATIENTS
Source text for Eikon: ID:nGNX1rWkV3
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study